Phase III Non-inferiority Clinical Study to Evaluate the Efficacy and Safety of Intravitreous PRO-169 Compared to Ranibizumab for Diabetic Macular Edema
Latest Information Update: 11 Dec 2023
At a glance
- Drugs Bevacizumab (Primary) ; Ranibizumab
- Indications Diabetic macular oedema
- Focus Registrational; Therapeutic Use
- Acronyms PRO-169
- Sponsors Laboratorios Sophia
Most Recent Events
- 05 Dec 2023 Planned End Date changed from 31 Dec 2023 to 31 Aug 2025.
- 05 Dec 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Aug 2025.
- 06 Feb 2022 New trial record